Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Global Market Report 2025

The chronic inflammatory demyelinating polyneuropathy (CIDP) market size has grown strongly in recent years. It will grow from $2.1 billion in 2024 to $2.38 billion in 2025 at a compound annual growth rate (CAGR) of 8.4%. The growth during the historic period can be credited to the increasing geriatric population, advancements in treatment options, greater awareness and early diagnosis, progress in immunology and autoimmune research, and the rising prevalence of autoimmune diseases.

The chronic inflammatory demyelinating polyneuropathy (CIDP) market size is expected to see strong growth in the next few years. It will grow to $3.11 billion in 2029 at a compound annual growth rate (CAGR) of 8.1%. The growth during the forecast period can be credited to an aging global population, a growing focus on rare diseases and autoimmune disorders, improved access to healthcare, increased patient advocacy and awareness campaigns, and advancements in healthcare infrastructure. Key trends include the rising prevalence of chronic inflammatory demyelinating polyneuropathy, advancements in treatment options, expanding research and development activities, the emergence of biosimilar therapies, and the development of personalized medicine approaches.

The increasing healthcare expenditure is expected to drive the growth of the chronic inflammatory demyelinating polyneuropathy (CIDP) market. The rise in healthcare spending is fueled by investments in medical infrastructure, increased demand for advanced treatments, expanded insurance coverage, and government efforts to improve healthcare access. As healthcare expenditure grows, it enhances access to cutting-edge treatments, early diagnosis, and better management of CIDP, all of which contribute to improved patient outcomes and quality of life. For instance, in May 2024, the Office for National Statistics, a UK-based government agency, reported a 5.6% increase in total healthcare expenditure from 2022 to 2023, a notable acceleration compared to the 0.9% growth seen in 2022. This growing healthcare expenditure is thus propelling the CIDP market.

Leading companies in the CIDP market are focusing on advancements such as intravenous immunoglobulin (IVIG) therapy to improve treatment effectiveness, enhance patient outcomes, and offer more targeted immune modulation for managing CIDP. IVIG therapy involves infusing concentrated antibodies from healthy donors to help modulate the immune system and reduce inflammation in autoimmune conditions. For example, in January 2024, Takeda Pharmaceutical Company Limited, a Japan-based biopharmaceutical company, received FDA approval for GAMMAGARD LIQUID as an IVIG therapy for adults with CIDP. This approval allows its use as an induction therapy, with an initial dose followed by maintenance doses to manage long-term disease and improve neuromuscular function.

In November 2024, Zai Lab Limited, a China-based biopharma company, partnered with argenx SE to introduce VYVGART Hytrulo as the first approved subcutaneous injection for CIDP in China. This partnership aims to provide a convenient, effective, and well-tolerated treatment, addressing unmet medical needs and improving patient outcomes. Argenx SE, a Netherlands-based biotechnology company, focuses on advancing therapies for severe autoimmune diseases, including CIDP.

Major players in the chronic inflammatory demyelinating polyneuropathy (CIDP) market are Pfizer Inc., Johnson & Johnson, Sanofi SA, Novartis AG, Takeda Pharmaceutical Company Limited, Baxter International Inc., CSL Behring (CSL Limited), Grifols S.A., Sun Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma Corporation, Octapharma AG, Cipla Inc., Hikma Pharmaceuticals plc, Halozyme Therapeutics, Hualan Biological Engineering Inc, argenx SE, Hovione, Nihon Pharmaceutical Co. Ltd., Bio Products Laboratory Ltd., and AdvaCare Pharma.

North America was the largest region in the chronic inflammatory demyelinating polyneuropathy (CIDP) market in 2024. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the chronic inflammatory demyelinating polyneuropathy (CIDP) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a rare autoimmune disorder characterized by progressive weakness and impaired sensory function due to nerve inflammation and demyelination. It occurs when the immune system attacks the myelin sheath of peripheral nerves, leading to muscle weakness, numbness, and coordination difficulties.

The primary treatment options for CIDP include intravenous immunoglobulin (IVIg), corticosteroids, plasmapheresis, physiotherapy, and other supportive therapies. IVIg is a blood-derived product containing antibodies that help regulate the immune system and treat autoimmune, immune deficiency, and inflammatory conditions. These treatments are administered through various routes, including intravenous, oral, and others. Diagnosis typically involves electrodiagnostic testing, nerve conduction studies, electromyography (EMG), spinal fluid analysis, and other diagnostic procedures. Treatments are distributed through hospitals, pharmacies, online pharmacies, and specialty clinics, with key end users including hospitals, research institutions, and homecare settings.

The chronic inflammatory demyelinating polyneuropathy (CIDP) market research report is one of a series of new reports that provides chronic inflammatory demyelinating polyneuropathy (CIDP) market statistics, including the chronic inflammatory demyelinating polyneuropathy (CIDP) industry global market size, regional shares, competitors with the chronic inflammatory demyelinating polyneuropathy (CIDP) market share, detailed chronic inflammatory demyelinating polyneuropathy (CIDP) market segments, market trends, and opportunities, and any further data you may need to thrive in the chronic inflammatory demyelinating polyneuropathy (CIDP) industry. This chronic inflammatory demyelinating polyneuropathy (CIDP) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The chronic inflammatory demyelinating polyneuropathy (CIDP) market consists of revenues earned by entities by providing services such as diagnostic testing, patient management, and therapeutic treatments. The market value includes the value of related goods sold by the service provider or included within the service offering. The chronic inflammatory demyelinating polyneuropathy (CIDP) market also includes sales of plasma exchange devices, monoclonal antibodies, nerve conduction study equipment, and physical therapy aids. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.